The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients

şen, ilker; GÜVEN ÇETİN, ELİF; Demir, Nazan

doi:10.14744/SEMB.2018.83604

The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients

Elif GÜVEN ÇETİN, (Sağlık Bilimleri Üniversitesi, İç Hastalıkları Anabilim Dalı, Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye)

Nazan DEMIR, (Eskişehir Osmangazi Üniversitesi, Sağlık Uygulama ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, Eskişehir, Türkiye)

İlker ŞEN (Sağlık Bilimleri Üniversitesi, Gastroenteroloji Anabilim Dalı, Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye)

Şişli Etfal Hastanesi Tıp Bülteni

5 0

Yıl: 2020 Cilt: 54 Sayı: 4 Sayfa Aralığı: 411 - 415 Metin Dili: İngilizce DOI: 10.14744/SEMB.2018.83604 İndeks Tarihi: 11-05-2021

The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients

Öz:

Objectives: Non-alcoholic fatty liver disease (NAFLD) is closely associated with diseases, such as obesity, diabetes mellitus, metabolic syndrome, which are characterized by insulin resistance. NAFLD is thought to be a manifestation of metabolic syndrome inthe liver. Liver fibrosis has a high prognostic significance in non-alcoholic steatohepatitis (NASH). In this study, the relationshipbetween insulin resistance and the histopathological changes in the liver was investigated in biopsy-proven NAFLD patients.Methods: In this study, 85 biopsy-proven NAFLD patients (64 NASH, 21 non-NASH) and 40 healthy control subjects were enrolled.Insulin resistance was calculated using the "homeostasis model assessment of insulin resistance" (HOMA-IR).Results: C reactive protein, total cholesterol, low-density lipoprotein, triglyceride, body mass index (BMI), HOMA-IR levels weresignificantly higher in the NAFLD group compared to the control group. In the NASH group, the HOMA-IR level was significantlyhigher than the non-NASH group (p=0.026). When NAFLD patients with advanced fibrosis (stage 3-4, n=27) and without fibrosis(stage 0-2, n=58) are compared, in advanced fibrosis group BMI (35.2±4.6 kg/m2 and 32.7±4.1 kg/m2, respectively; p=0.031) andHOMA-IR (6.3 [5.8-6.8] and 3.4 [2.6-4.8], respectively, p=0.001) levels were higher significantly. In the covariance analysis, when confounding factors, such as BMI, age and gender, were corrected, it was observed that the elevation of HOMA-IR level in the advancedfibrosis group continued statistically significantly.Conclusion: HOMA-IR levels were high in NAFLD patients with advanced fibrosis. HOMA-IR, which can be easily measured in dailypractice, is an independent predictor for fibrosis.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol 2014;20:9330–7.
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107:811–26.
3. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–73.
4. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595–602.
5. Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012;30:158–62.
6. Baran B, Akyüz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol. 2014;20:14219–29.
7. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol 2009;2:157–63.
8. Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103–10.
9. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410–5.
10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
11. Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 2005;22:330–8.
12. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40 Suppl 1:S17–29.
13. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–54.
14. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987–1000.
15. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792–8.
16. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634–42.
17. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738–44.
18. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356–62.
19. Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology 2016;63:107–16.
20. Svegliati-Baroni G, Bugianesi E, Bouserhal T, Marini F, Ridolfi F, Tarsetti F, et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in nonalcoholic fatty liver disease. Gut 2007;56:1296–301.
21. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179–87.
22. Korkmaz H, Unler GK, Gokturk HS, Schmidt WE, Kebapcilar L. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test. Eur J Gastroenterol Hepatol 2015;27:1137– 43.
23. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005;54:3140–7.
24. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004;19:694–8.

APA	GÜVEN ÇETİN E, Demir N, şen i (2020). The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. , 411 - 415. 10.14744/SEMB.2018.83604
Chicago	GÜVEN ÇETİN ELİF,Demir Nazan,şen ilker The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. (2020): 411 - 415. 10.14744/SEMB.2018.83604
MLA	GÜVEN ÇETİN ELİF,Demir Nazan,şen ilker The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. , 2020, ss.411 - 415. 10.14744/SEMB.2018.83604
AMA	GÜVEN ÇETİN E,Demir N,şen i The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. . 2020; 411 - 415. 10.14744/SEMB.2018.83604
Vancouver	GÜVEN ÇETİN E,Demir N,şen i The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. . 2020; 411 - 415. 10.14744/SEMB.2018.83604
IEEE	GÜVEN ÇETİN E,Demir N,şen i "The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients." , ss.411 - 415, 2020. 10.14744/SEMB.2018.83604
ISNAD	GÜVEN ÇETİN, ELİF vd. "The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients". (2020), 411-415. https://doi.org/10.14744/SEMB.2018.83604

APA	GÜVEN ÇETİN E, Demir N, şen i (2020). The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. Şişli Etfal Hastanesi Tıp Bülteni, 54(4), 411 - 415. 10.14744/SEMB.2018.83604
Chicago	GÜVEN ÇETİN ELİF,Demir Nazan,şen ilker The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. Şişli Etfal Hastanesi Tıp Bülteni 54, no.4 (2020): 411 - 415. 10.14744/SEMB.2018.83604
MLA	GÜVEN ÇETİN ELİF,Demir Nazan,şen ilker The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. Şişli Etfal Hastanesi Tıp Bülteni, vol.54, no.4, 2020, ss.411 - 415. 10.14744/SEMB.2018.83604
AMA	GÜVEN ÇETİN E,Demir N,şen i The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. Şişli Etfal Hastanesi Tıp Bülteni. 2020; 54(4): 411 - 415. 10.14744/SEMB.2018.83604
Vancouver	GÜVEN ÇETİN E,Demir N,şen i The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. Şişli Etfal Hastanesi Tıp Bülteni. 2020; 54(4): 411 - 415. 10.14744/SEMB.2018.83604
IEEE	GÜVEN ÇETİN E,Demir N,şen i "The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients." Şişli Etfal Hastanesi Tıp Bülteni, 54, ss.411 - 415, 2020. 10.14744/SEMB.2018.83604
ISNAD	GÜVEN ÇETİN, ELİF vd. "The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients". Şişli Etfal Hastanesi Tıp Bülteni 54/4 (2020), 411-415. https://doi.org/10.14744/SEMB.2018.83604